- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03596632
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
December 5, 2018 updated by: Hoffmann-La Roche
A Phase 1 Open-label Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C/12C]-Labeled Fenebrutinib in Healthy Volunteers
The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Covance Clinical Research Unit, Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects, between 18 and 60 years of age, inclusive
- Within body mass index range 18 to 32 kg/m2, inclusive
- In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG), vital signs, and physical examination
- For males who are sterile: agreement to use a condom with a fertile or pregnant female partner from Day -1 until 90 days following Study Completion; for males who are fertile: agreement to use a condom with spermicide with a fertile or pregnant female partner from Day -1 until 90 days following Study Completion
Exclusion Criteria:
- History or symptoms of any significant disease
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
- History of stomach or intestinal surgery or resection, except appendectomy, hernia repair, and cholecystectomy
- History of malignancy, except for non-melanoma skin carcinoma with 3-year disease-free follow-up
- Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Day -1
- Exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day -1
- Participation in a radiolabeled drug study in which exposures are known to the Investigator within 4 months prior to Day -1, or participation in a radiolabeled drug study in which exposures are not known to the Investigator within 6 months prior to Day -1. The total 12-month exposure from this study and a maximum of 2 other studies must be within the Code of Federal Regulations (CFR) recommended levels considered state (per 21 CFR 361.1), e.g. less than 5,000 mrem whole body annual exposure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Oral Solution Dose
Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
|
200-mg (100 µCi) oral solution 14C/12C]-fenebrutinib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Percentage of the Total Radioactive Dose Administered Excreted from Urine and Feces"; TimeFrame: "Day 1 to end of study (approximately 35 days post-dose)
Time Frame: Screening to end of study (approximately 35 days post-dose)
|
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
A SAE is defined as any AE that can be fatal, life threatening, prolongs inpatient hospitalization, significant disability, congenital anamoly, is a significant medical event in the Investigator's judgment.
|
Screening to end of study (approximately 35 days post-dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Concentration (Cmax) of Fenebrutinib and its Metabolites
Time Frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
|
Time to Observed Maximum Concentration (Tmax) of Fenebrutinib and its Metabolites
Time Frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
|
Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Fenebrutinib and its Metabolites
Time Frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
|
Area under the Concentration-Time Curve Extrapolated to Infinity (AUC0-infinity) of Fenebrutinib and its Metabolites
Time Frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
|
Cumulative Percent of Total Radioactivity Excreted in Urine Over the Sampling Interval (Total % Feu)
Time Frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
|
Cumulative Percent of Total Radioactivity Excreted in Feces Over the Sampling Interval (Total % Fef)
Time Frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
Day 1 pre-dose to end of study (approximately 35 days post-dose)
|
|
Number of Participants With Clinical Significant Changes in Vital Signs
Time Frame: Screening up to Day 31
|
Vital signs incudes oral temperature, respiratory rate, supine blood pressure and pulse.
|
Screening up to Day 31
|
Number of Participants With Clinical Significant Changes in Physical Examination Findings
Time Frame: Day -1, 28
|
Physical examination will consist of an assessment of general appearance, skin, thorax/lungs, abdomen, lymph nodes, head, ears, eyes, nose, throat, neck (including thyroid); and cardiovascular, musculoskeletal, and neurological systems.
|
Day -1, 28
|
Number of Participants With Clinical Significant Changes in Clinical Laboratory Results
Time Frame: Screnning, Day -1, 2, 4, 28
|
Laboratory analysis include chemistry panel, complete blood count and urinalysis.
|
Screnning, Day -1, 2, 4, 28
|
Number of Participants With Clinical Significant Changes in Electrocardiograms (ECGs)
Time Frame: Screening, Day-1, 1 (Pre-dose; 1, 3 hours [h] post-dose), 28, 31
|
Screening, Day-1, 1 (Pre-dose; 1, 3 hours [h] post-dose), 28, 31
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2018
Primary Completion (Actual)
August 23, 2018
Study Completion (Actual)
August 23, 2018
Study Registration Dates
First Submitted
July 13, 2018
First Submitted That Met QC Criteria
July 13, 2018
First Posted (Actual)
July 24, 2018
Study Record Updates
Last Update Posted (Actual)
December 6, 2018
Last Update Submitted That Met QC Criteria
December 5, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- GP40605
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbNot yet recruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on Fenebrutinib
-
Genentech, Inc.Terminated
-
Genentech, Inc.CompletedLymphocytic Leukemia, Chronic, Diffuse Large B-Cell LymphomaUnited States, Australia
-
Hoffmann-La RocheActive, not recruitingMultiple Sclerosis, Primary ProgressiveUnited States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
-
Hoffmann-La RocheActive, not recruitingRelapsing Multiple SclerosisCzechia, Serbia, United States, Croatia, Bosnia and Herzegovina, Slovakia
-
Hoffmann-La RocheActive, not recruitingRelapsing Multiple SclerosisUnited States, Korea, Republic of, India, Brazil, Poland, Canada, Bulgaria, United Kingdom, France, Greece, Italy, Russian Federation, Turkey, Mexico, Austria, Denmark, Guatemala
-
Hoffmann-La RocheActive, not recruitingRelapsing Multiple SclerosisUnited States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...